Ablukast |
| Catalog No.GC64356 |
Ablukast(Ro 23-3544)는 특이적이고 활성인 류코트리엔 수용체 길항제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 96566-25-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3].
Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2].
Ablukast (Ro 23-3544) is tested for its efficacy in modulating dinitrofluorobenzene (DNFB)-induced allergic and croton oil-induced irritant contact dermatitis in mouse ears. Treatment shortly after elicitation of the dermatitis, and for up to 5 days thereafter, was moderately effective in suppressing DNFB-induced ear swelling in a dose-dependent fashion. Daily pre-treatment of the ears for 1 week causes a more marked reduction of DNFB-induced ear swelling during the first 48 h after elicitation[2].
[1]. M O’Donnell, et al. Pharmacological profile of Ro 23-3544, a new aerosol active leukotriene receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:512-8.
[2]. T Rosenbach, et al. Studies on the role of leukotrienes in murine allergic and irritant contact dermatitis. Br J Dermatol. 1988 Jan;118(1):1-6.
[3]. Hans-Michael Eggenweiler, et al. Pyrrolopyrimidines as phosphodiesterase VII inhibitors. US7498334B2.
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *